Edgen Stock·Dec 16 2025, 00:06Back
Immunome Stock Surges On Positive Cancer Drug Data
Edgen Stock·Dec 16 2025, 00:06
[1] Aviceda geographic atrophy hopeful fails to top Astellas med in phase 2 - Fierce Biotech (https://www.fiercebiotech.com/biotech/aviceda ...)[2] Aviceda Therapeutics Announces Phase 2b SIGLEC Results for AVD-104 in Geographic Atrophy - BioSpace (https://www.biospace.com/press-releases/avice ...)[3] Immunome’s desmoid tumor treatment triumphs in phase 3, setting up approval filing - Fierce Biotech (https://www.fiercebiotech.com/biotech/immunom ...)
